Idogen demonstrates proof-of-principle in a model of autoimmune disease
Idogen has, as previously announced, decided to evaluate the potential of the company's technology in a group of autoimmune diseases where there is a high unmet medical need and where the treatment could be granted orphan drug designation. The company has now successfully completed a pre-clinical study in a model of autoimmune uveitis, a serious disease which can lead to blindness. In the model of induced autoimmune uveitis, groups of animals were treated with zebularine by injection. The group of animals treated with zebularine showed a significant positive effect in symptom relief